Business Context and Reporting Period
This Form 8-K Current Report was filed by PharmAthene, Inc. (not Altimmune, Inc.) on March 23, 2009. The filing reports the entry into material definitive agreements regarding a public offering of common stock and warrants.
Key Financial Metrics
- Gross Proceeds: Approximately $5.5 million.
- Shares Issued: 2,116,055 shares of common stock.
- Offering Price: $2.60 per share.
- Warrants Issued: Warrants to purchase up to 705,354 additional shares.
- Warrant Exercise Price: $3.00 per share.
- Warrant Term: Exercisable beginning 6 months after issuance until September 27, 2014.
- Placement Agent Fees: Estimated at $357,613 (6.5% of proceeds).
- Financial Advisory Fee: Approximately $47,500 paid to WBB Securities, LLC.
Material Changes
The filing details a capital raise event rather than operational performance changes. The company executed a Securities Purchase Agreement and Engagement Letters with Rodman & Renshaw, LLC (lead agent) and Caris & Company (co-agent) to facilitate the offering. The transaction was conducted as a shelf takedown from a registration statement declared effective on February 12, 2009.
Outlook, Risks, and Unusual Items
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard legal disclaimers regarding the agreements. The warrants are subject to adjustment in the event of stock splits, dividends, business combinations, or asset sales. The filing explicitly states that the agreements are not intended as documents for the public to obtain factual information about the company's current state of affairs.
Investor Verification Checklist
- Verify the company name is PharmAthene, Inc., as the input metadata incorrectly listed Altimmune, Inc.
- Confirm the net proceeds after deducting the $357,613 placement fees and $47,500 advisory fee.
- Review the attached Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Check the prospectus supplement dated March 24, 2009, for full terms of the offering.
- Monitor the warrant exercise window starting 6 months post-issuance.